Deadline Alert: Your Last Chance for Certain 2013 Retirement Contributions Is Here
8 Foolproof Ways to Grow Your Savings
How to Have a Successful Money Talk With Your Significant Other
After Market: Calm Optimism as Stocks Hold Steady, Gold Sinks Below $1,200
Is Celgene the Perfect Stock?
Merck has confirmed that it halted its late-stage student of vorapaxar, a potential clot-preventing drug, after an increased risk of bleeding in some patients.